In May 2024, we attended IMMUNOLOGY2024, the annual meeting of the American Association of Immunologists in Chicago, and recorded daily episodes discussing highlights of the previous 24 hours. Here is the fourth of five special episodes from the meeting, where Brenda and Jason highlight discussions on tumor-infiltrating lymphocyte therapy, chaired by former podcast guest Dr. Kristin Anderson, as well as fueling T cell fate decision during infection with an initial focus on immunometabolism.

IMMUNOLOGY2024™: Day 4
The Immunology Podcast
Advancements in TIL Therapy and Vaccine-Prime T Cell Research
This chapter highlights a successful phase two trial of tumor-infiltrating lymphocyte therapy for metastatic melanoma, which achieved a 31% response rate and prompted FDA acceleration. It also discusses future trials, the integration of PD-1 inhibitors, and innovative vaccination strategies to enhance adoptive immunotherapy.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.